NCT02798757 Evaluation of the Tubular Effects of Dapagliflozin Using 1HNMR Spectroscopy Status COMPLETED Phase PHASE4
NCT02796170 Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes Status COMPLETED Phase PHASE4
NCT02765204 A Single-dose Cross-over Study to Assess Direct and Indirect Effects of Dapagliflozin on Pancreatic Alpha and Beta Cells in Patients With Type 2 Diabetes Status COMPLETED Phase PHASE4
NCT02725593 Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years Status COMPLETED Phase PHASE3
NCT02719756 Effect of SGLT-2 Inhibitor Dapagliflozin on Glycemic Variability in Patients With Diabetes Mellitus Type 2 Status UNKNOWN Phase PHASE4
NCT02719132 Effect of DapagliFLOzin on Quality of Life in Patients With Type 2 Diabetes in a Real Clinical PrActice Status WITHDRAWN Phase PHASE4
NCT02700334 Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes Status COMPLETED Phase PHASE4
NCT02695810 The PRE-D Trial: Effect of Dapagliflozin, Metformin and Physical Activity in Pre-diabetes Status COMPLETED Phase PHASE2
NCT02681094 A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes Status COMPLETED Phase PHASE3
NCT02653482 Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure Status COMPLETED Phase PHASE4
NCT02616666 A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients Status COMPLETED Phase PHASE4
NCT02610088 Effect of Dapagliflozin on Vascular Functions in Patients With Type 2 Diabetes Compared to Gliclazide Status COMPLETED Phase PHASE4
NCT02608905 Effect of Dapagliflozin on Inflammation and Endothelial Function Status TERMINATED Phase PHASE4
NCT02592421 SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2 Status COMPLETED Phase PHASE3
NCT02585804 Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects Status COMPLETED Phase PHASE4
NCT02577159 Dapagliflozin on Hyperlipidemia and Insulin Resistance in Type 2 Diabetic Patients (DAPHNIS Study) Status UNKNOWN Phase PHASE4
NCT02558270 Effects of SGLT-2 Inhibition on Hepatic Glucose and Energy Metabolism Status UNKNOWN Phase PHASE2
NCT02532855 A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838) Status COMPLETED Phase PHASE3